Cyfuse Biomedical K.K. is a biotechnology startup founded in 2010 that is making significant strides in the medical field through its groundbreaking 3D tissue-engineering technology. The company's latest research achievements include the development of a scaffold-free functional 3D-printed liver for drug discovery and a scaffold-free Bio 3D conduit for peripheral nerve regeneration. These cutting-edge advancements have been reported in notable publications such as Elsevier and ResearchGate.
Notably, Cyfuse Biomedical K.K. received its latest Venture Round investment on 29 January 2021 from Fujimori Kogyo, indicating confidence from investors in the company's potential to drive impactful innovations in the fields of biotechnology and healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 | Fujimori Kogyo | 29 Jan 2021 |
| Non Equity Assistance | Unknown | 1 | VentureOut | 29 Sep 2020 |
| Venture Round | Unknown | 1 | Iwatani Corporation | 07 Jul 2020 |
| Venture Round | ¥200.00M | 1 |
|
03 Apr 2019 |
| Corporate Round | ¥150.00M | 1 | Taiyo Holdings Co. | 15 Feb 2019 |
No recent news or press coverage available for Cyfuse Biomedical K.K..
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
